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METHODOLOGICAL ARTICLE
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Abstract
Background: The coronavirus disease 2019 (COVID-19) pandemic has caused a
large surge of acute respiratory distress syndrome (ARDS). Prior phase I trials (non–
COVID-19) demonstrated improvement in pulmonary function in patients ARDS
using fibrinolytic therapy. A follow-up trial using the widely available tissue-type
plasminogen activator (t-PA) alteplase is now needed to assess optimal dosing and
safety in this critically ill patient population.
Objective: To describe the design and rationale of a phase IIa trial to evaluate the
safety and efficacy of alteplase treatment for moderate/severe COVID-19–induced
ARDS.
Patients/Methods: A rapidly adaptive, pragmatic, open-label, randomized, controlled, phase IIa clinical trial will be conducted with 3 groups: intravenous alteplase
50 mg, intravenous alteplase 100 mg, and control (standard-of-care). Inclusion criteria are known/suspected COVID-19 infection with PaO2/FiO2 ratio <150 mm Hg
for > 4 hours despite maximal mechanical ventilation management. Alteplase will be
delivered through an initial bolus of 50 mg or 100 mg followed by heparin infusion
for systemic anticoagulation, with alteplase redosing if there is a >20% PaO2/FiO2
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improvement not sustained by 24 hours.
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domization. Other outcomes include ventilator- and intensive care unit–free days,

Results: The primary outcome is improvement in PaO2/FiO2 at 48 hours after ransuccessful extubation (no reintubation ≤3 days after initial extubation), and mortality.
Fifty eligible patients will be enrolled in a rapidly adaptive, modified stepped-wedge
design with 4 looks at the data.
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Conclusion: Findings will provide timely information on the safety, efficacy, and optimal dosing of t-PA to treat moderate/severe COVID-19–induced ARDS, which can be
rapidly adapted to a phase III trial (NCT04357730; FDA IND 149634).
KEYWORDS

acute respiratory distress syndrome, clinical trial, coagulopathy, COVID-19, fibrinolysis
shutdown, tissue-type plasminogen activator
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Essentials
• Fibrinolytics have been used in phase I trials to treat acute respiratory distress syndrome (ARDS) with efficacy and low risk of bleeding
complications.
• Coronavirus disease 2019 (COVID-19) is associated with microthrombi of the lungs and ARDS.
• STARS is an adaptive, pragmatic, open-label, phase IIa trial using tissue-type plasminogen activator (t-PA) to treat COVID-19–related ARDS.
• Two different dosing regimens of t-PA will be used to test for efficacy in improving oxygenation at 48 hours from study enrollment.

1 | INTRODUCTION

presence of mononuclear cell infiltrates and megakaryocytes,

The worldwide incidence of coronavirus disease 2019 (COVID-19)

culature.1,3 The concept of accumulation of pulmonary micro-

continues to rise, taxing the health care and economic resources of

thrombi leading to death dates back to 1845.13 The angiographic

countries throughout the developed world. Based on the clinical ex-

appearance of filling defects of the pulmonary vasculature in

perience in China and Italy, it is estimated that 5% to 27% of hos-

patients with ARDS has been associated with a high mortality

pitalized patients with COVID-19 will require prolonged intensive

rate for decades.14-17 Animal models of irreversible shock have

care,1-6 with 50% to 99% requiring mechanical ventilation (MV) for

demonstrated clots in organs driving organ failure.18,19 This can

viral-induced pneumonitis progressing to acute hypoxemic respira-

be reversed with preemptive heparin 20,21 or postshock fibrino-

as well as fibrin-platelet microthrombi in the pulmonary vas-

tory failure and acute respiratory distress syndrome (ARDS).
7,9

patients requiring MV, the reported mortality exceeds 50%

2,7,8

In

lytics. 22 Autopsies of critically ill patients also demonstrated

and ap-

clots in the organs of patients in the intensive care unit who

proached 90% in a recent report from New York City.10 There is no

died from organ failure.19,23 These observations were eventually

specific treatment for COVID-19 ARDS other than routine mechani-

translated to 2 separate phase I human trials, 24,25 which were

cal ventilation, although prone positioning seems to be particularly

not followed up.

effective in this population,11 either as a consequence of enhanced

Given these vascular and hematologic findings and the dis-

alveolar drainage or redistribution of perfusion to better aerated por-

tinct nature of the COVID-19 ARDS, with preserved pulmonary

tions of the lungs.

mechanics, we postulate that this advanced ARDS is due to the

A remarkable feature of the pulmonary pathophysiology in

microthrombosis and resistance to clot lysis in the pulmonary

COVID-19 ARDS is the preservation of relatively normal lung

circulation. We believe these factors directly contribute to the

compliance and a low incidence of barotrauma12 suggesting ex-

high-shunt type of hypoxemic respiratory failure seen in COVID-

tensive shunting, ventilation-perfusion mismatch, and loss of

19 ARDS. We hypothesized that administration of alteplase, a

regulation of alveolar perfusion. Autopsy and surgical specimens

tissue-plasminogen activator (t-PA), followed by systemic an-

in these patients show a range of pathologic findings including

ticoagulation will improve the PaO2 /FiO2 ratio 48 hours after

diffuse alveolar damage, fibrin accumulation in the alveoli, the

treatment.
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1.1 | Objective
We aimed to describe the design and rationale of a phase IIa trial
(NCT04357730) that will evaluate the safety and efficacy of tPA
(alteplase) treatment for moderate to severe ARDS in the setting
of COVID-19 infection.

2 | METHODS
This is a phase IIa, open-label clinical trial with a modified stepped-

MOORE et al.

TA B L E 1

Inclusion and exclusion criteria for the STARS trial

Inclusion criteria: age 18-75 y old with known or suspected COVID19 infection with a PaO2/FiO2 ratio <150 (at sea level) or (inferred
PaO2/FiO2 ratio from SpO2 if an arterial blood gas is unavailable)
persisting for >4 h despite maximal mechanical ventilation
management according to each institution's ventilation protocols.
Absolute exclusion criteria (documented at the time of enrollment):
Stroke or inability to demonstrate a normal neurological exam
unless a CT scan within 4.5 h of enrollment excludes a cerebral
vascular event
Active bleeding

wedge design, testing systemic administration of fibrinolytic ther-

Acute myocardial infarction or history of myocardial infarction
within the past 3 wk or cardiac arrest during hospitalization

apy with alteplase (using Activase manufactured by Genentech,

Hemodynamic instability with noradrenaline >0.2 µg/kg/min

Inc) versus standard of care for patients infected with COVID-19
resulting in severe ARDS. The study is registered at clinicaltrials.gov
(NCT04357730), has received approval to proceed by the US Food
and Drug Administration (FDA; IND 149634), and by all institutions’
institutional review boards (IRBs). The design is a rapidly adaptive,
pragmatic clinical trial, with 3 interim analyses and 1 final look at the
data. Preplanned adaptations described below will be contemplated
at each interim analysis or earlier if recommended by the Data Safety
Monitoring Board (DSMB).

2.1 | Inclusion criteria

Acute renal failure requiring dialysis
Liver failure (escalating liver failure with total bilirubin > 3 mg/dL)
Cardiac tamponade
Bacterial endocarditis
Severe uncontrolled hypertension defined as SBP >185 mm Hg or
DBP >110 mm Hg
History of severe head injury within prior 3 mo, or prior history of
intracranial hemorrhage
Seizure during prehospital course or during hospitalization for
COVID-19
Diagnosis of brain tumor, arteriovenous malformation (AVM), or
ruptured aneurysm
Currently on ECMO

We will include patients ages 18-75 years, with known or suspected COVID-19 infection, with a normal neurological exam
at time of enrollment (if patient is on paralytics, the patient has
been awakened and showed no new neurological deficits in a
complete neurological exam or had a magnetic resonance imaging
(MRI)/computed tomography (CT) scan in the past 4.5 hours with
no evidence of stroke), with a PaO2/FiO2 ratio <150 mm Hg (at
sea level or adjusted for altitude) persisting for >4 hours despite
maximal MV management according to each institution’s ventila-

Major surgery or major trauma within the past 2 wk
GI or GU bleed within the past 3 wk
Known bleeding disorder
Arterial puncture at a noncompressible site within the past 7 d
Lumbar puncture within past 7 d
Pregnancy
INR > 1.7 (with or without concurrent use of warfarin)
Platelet count <100 × 109/L or history of HITT

tion protocols (FiO2 ≥ 60% and positive end-expiratory pressure

Fibrinogen <300 mg/dL

[PEEP] ≥ 10 cm H2O). If obtaining arterial blood gases is not pos-

Known abdominal or thoracic aneurysm

sible due to a surge-related shortage of blood gas syringes, as we

History of CNS malignancy or CNS metastasis within past 5 y

have experienced previously, we will infer the PaO2/FiO2 ratio
from percent saturation of hemoglobin with oxygen as measured

History of non-CNS malignancy within the past 5 y that
commonly metastasizes to the brain (lung, breast, melanoma)

by pulse oximetry (SpO2), using the nonlinear imputation devel-

Prisoner status

oped by the National Heart, Lung, and Blood Institute’s PETAL
(Prevention and Early Treatment of Acute Lung Injury) Network
Collaborators. 26 A normal neurological exam or CT/MRI scan to

1. Group tPA50 (n = 20) will receive 50 mg of alteplase intravenous bolus administration over 2 hours, given as a 10-mg

demonstrate no evidence of an acute stroke is needed due to

push followed by the remaining 40 mg over a total time of

recent reports of large-vessel stroke as a presenting feature of

2 hours. Immediately following the alteplase infusion, 5000 U

COVID-19 in young individuals. 27

of unfractionated heparin (UFH) will be delivered; the heparin

Patients will be enrolled based on clinical characteristics, with-

drip will be continued to maintain the activated partial throm-

out consideration of language (using hospital interpreters and trans-

boplastin time (aPTT) at 60 to 80 seconds (2.0-2.5 times the

lated consent), race/ethnicity, or sex/gender. Patients are eligible to

upper limit of normal). This t-PA protocol is a modification

participate even if they are concurrently enrolled in other COVID-19

of the GUSTO (Global Utilization of Streptokinase and Tissue

therapeutic trials. Exclusion criteria are listed in Table 1.

Plasminogen Activator for Occluded Coronary Arteries) I to III

There are 3 treatment arms:

trials.28,29

|
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2. Group tPA100 (n = 20) will receive 100 mg of t-PA intravenous

determined by the Pocock method to maintain overall experiment

bolus administration over 2 hours, given as a 10-mg push followed

error at <0.05. Preplanned adaptations described below will be

by the remaining 90 mg over a total time of 2 hours. Immediately

contemplated at each interim analysis or earlier if recommended

following the t-PA infusion, 5000 U of UFH will be delivered, and

by the DSMB. For rapid efficacy assessment to isolate the arm(s)

the heparin drip will be continued to maintain the aPTT at 60 to

with the highest likelihood of success and lowest bleeding risk, we

80 seconds (2.0-2.5 times the upper limit of normal). This t-PA

will deploy each intervention arm sequentially up to each interim

protocol is similar to that used by Konstantinides et al.30

analysis, in a modified stepped-wedge fashion31, with preplanned

3. Control: institution’s standard-of-care protocol for ARDS.
Rebolusing of tPA is permitted in the first two intervention groups,
particularly in those patients who show an initial transient response, but

adaptations(below) at each interim analysis Figure 1.

2.5 | Data collection and storage

is not sustained (<50% PaO2/FiO2 improvement by 24 hours). All exclusion criteria (Table 1) also apply to the second t-PA (alteplase) bolus.
Other modifications of the alteplase dosing are as follows:

Study data will be collected and managed using REDCap (Research
Electronic Data Capture) electronic data capture tools hosted by the
University of Colorado Anschutz Medical Campus.32

1. Fibrinogen monitoring: For all t-PA administration groups, fibrinogen levels will be measured before and after t-PA intravenous bolus, 6 hours after the start of the infusion, then every

2.6 | Randomization

6 hours for first 24 hours, and once a day for 6 days following
treatment intervention in all the groups (see detailed lab testing

All randomizations will be conducted intrahospital (ie, no cluster ran-

schedule below). If fibrinogen levels fall below 300 mg/dL, the

domization) to avoid the confounding effect of practice variation,

second bolus of t-PA (alteplase) will not be given.

in blocks of 10 to allow better distribution between groups at each

2. Heparin dosing: An infusion of unfractionated heparin will be con-

interim analysis. It will be done by the Data Coordinating Center and

tinued for up to 7 days or until the patient is extubated and has

automated in a REDCap instrument. Upon confirmed eligibility and

an O2 requirement of ≤4 L/min by nasal cannula, and titrated to

consent, the REDCap instrument will reveal the assignment (Group

maintain the activated partial thromboplastin time to 60 to 80 sec-

tPA50, Group tPA100, Control) to the pharmacy of the enrolling in-

onds (2.0-2.5 times the upper limit of normal). The goal of this treat-

stitution, which will then release the drug if the patient was assigned

ment is to prevent recurrent microvascular thrombotic hypoxemia

to one of the intervention groups. Time 0 is assigned as the time of

or macrovascular complications (stroke, myocardial infarction, or

randomization. We anticipate that each of the 5 centers will enroll

venous thromboembolism) due to possible rebound t-PA effects

5 to 10 patients.

causing hypercoagulability. If necessary, an infusion of antithrombin concentrate will be administered in heparin-resistant patients.

2.2 | Diverse positioning and/or paralytic agents for
ventilation

2.7 | Sample size rationale
The sample size was fixed at n = 50 (with 20 patients in each intervention group and 10 patients in the control group) due to budgetary and feasibility constraints. The minimum detectable difference

If the position or use of paralytics must be changed before the 24-

was then calculated using PASS version 14.0 (NCSS LLC, Kaysville,

and 48-hours post-randomization, the PaO2/FiO2 measured im-

UT, USA), focusing on the primary outcome (PaO2/FiO2 improvement)

mediately before these changes (within <6 hours of the 48-hour

and assuming (i) power = 80%, confidence = 95%, and four sequential

postrandomization end point) will be used as primary outcome.

tests (3 interim + 1 final), using the Pocock method to determine test
boundaries; (ii) potential improvement assumptions based on a previ-

2.3 | Outcomes

ous study25 as well as a more favorable scenario with mean baseline
PaO2/FiO2 = 149 with an overestimated standard deviation of 100, (iii)
design effect = 1.12 due to the study’s multicenter nature (intraclass

The primary outcome of interest is change in PaO2/FiO2 at 48 hours

correlation coefficient = 0.03,33,34 average cluster = 5); and (iv) 20%

from randomization. Secondary outcomes are listed in Table 2.

inflation to account for premature death or withdrawal for any reasons.
A sample size of 50 (20 in each intervention group and 10 in the

2.4 | Rapidly adaptive design (Figure 1)

control group) patients would detect a ≥68% improvement in PaO2/
FiO2 between the 2 intervention groups and ≥73% improvement between intervention groups and controls. While balanced group sizes

The design is a rapidly adaptive, pragmatic clinical trial, with 3 in-

will maximize a study’s statistical power, unequal randomization ra-

terim analyses and 1 final look at the data, with test boundaries

tios will only significantly reduce the power of a study if the ratio is

988
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Primary and secondary outcomes for the STARS trial

Outcome

Timing

Primary outcome: PaO2/FiO2 improvement from pre-to-post intervention

48 h after randomization.

Secondary outcomes
Achievement of PaO2/FiO2 ≥200 or 50% increase in PaO2/FiO2 (whichever is lower)

48 h after randomization

National Early Warning Score (NEWS)a

48 h after randomization
14 d

NIAID ordinal scale

b

Reduction of FiO2 <80% (if started on higher concentration)
Return to supine or lateral position (if started in prone position)
Reduction of positive end expiratory pressure
Reduction of inhaled prostonoids (if started before t-PA therapy)
Reduction of inhaled nitric oxide (if started before t-PA therapy)
Reduction of paralytic (if on before t-PA therapy)
Reciever operating characteristic curve of coagulation variables associated with achievement a PaO2/FiO2 >50%
Reciever operating characteristic curve of coagulation variables associated with bleeding complications
48 h in-hospital mortality
14 d in-hospital mortality

14 d

28 d in-hospital mortality

28 d

ICU-free days (up to 28 d)

28 d

In-hospital coagulation-related event-free (arterial and venous) days (up to 28 d)

28 d

Ventilator-free days (up to 28 d)

28 d

Successful extubation (no reintubation <3 d after initial extubation)

28 d

Survival to discharge

Discharge

a

National Early Warning Score (NEWS2): based on 7 clinical parameters (respiration rate, oxygen saturation, any supplemental oxygen, temperature,
systolic blood pressure, heart rate, level of consciousness); bNIAID ordinal scale: The ordinal scale is an assessment of the clinical status as follows:
(i) death; (ii) hospitalized, on invasive mechanical ventilation or extracorporeal membrane oxygenation; (iii) hospitalized, on noninvasive ventilation
or high-flow oxygen devices; (iv) hospitalized, requiring supplemental oxygen; (v) hospitalized, not requiring supplemental oxygen–requiring ongoing
medical care (COVID-19 related or otherwise); (vi) hospitalized, not requiring supplemental oxygen—no longer requires ongoing medical care; (vii)
not hospitalized, limitation on activities and/or requiring home oxygen; (viii) not hospitalized, no limitations on activities (we will combine 7 and 8 as
discharge from hospital to home, as the trial is limited to in-hospital morbidity/mortality).

3:1 or more. Reasons for the unequal randomization include (i) more

2.9 | Criteria for stopping for futility

safety information, an essential component of a phase IIa study; (ii)
experience with dosing of t-PA; and (iii) to allow 3 equal sequential

We will follow the guidelines established by Jitlal et al36.These criteria

phases that would inform the remainder of the trial.35 The initial 2

are (i) low conditional power (<15%), calculated using bootstrapping

phases (t-PA 50 mg vs control; t-PA 100 mg vs control) will provide a

simulations, based on the target minimum differences for all primary

signal that allows the termination of the control arm.

and secondary outcomes; (ii) observed difference size in the primary or

Recruitment will assume at least a 30% increase to account for

secondary outcomes favor the control group (<5%); (iii) the DSMB and

refusal or inability to consent. We anticipate enrolling enough indi-

trial team agree that enough patients and events have been observed

viduals to result in a sample of 50 eligible patients, to be reevaluated

so far to produce a reliable effect; (iv) only 1 center interested in con-

during each of the interim analyses. A legally authorized represen-

tinuing enrollment; and (v) no evidence of an effect in any prespecified

tative, as defined by each state and each institution’s legislation and

subgroups. If the DSMB deemed the adverse events profile acceptable,

policies, will be able to consent.

we may wish to continue to ensure that a modest effect is not missed.

2.8 | Criteria for stopping the clinical trial early for
efficacy or harm

2.10 | Preplanned adaptations at each
interim analysis

Criteria include reaching adjusted P value for the primary outcome

The study interim analyses will be used to propose preplanned mod-

and at least 1 of the secondary outcomes at all follow-up time points,

ifications based on observed effects, recruitment, eligibility, and

or DSMB deemed the harm profile unacceptable.

other aspects of the study as determined below.

|
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Sequential deployment of the study groups

Eligible patients
randomized
within
institutions

Eligible patients
randomized
within
institutions

tPA50
(n = 5)
and
Control
(n = 5)

tPA100
(n = 5)
and
Control
(n = 5)

1st interim
analysis:
adaptations
as needed

10 patients

FIGURE 1

Eligible patients
randomized
within
institutions

2nd interim tPA50
(n = 5)
analysis:
and
adaptations
Control
as needed
(n = 5)

20 patients

3rd interim
analysis:
adaptations
as needed

30 patients

Decisions at this point:
Superiority of one growth?
Randomization within
centers if no superiority?
Eliminate one or more
groups?
changes in doses,sample
size, study groups inclusion
criteria,etc.

50 patients

Study design of the STARS trial

• Drop/add study arms: Deploying study arms sequentially (vs in

• Cessation rules: Based on interim analyses, coagulation and

parallel) allows sufficient sample sizes in each arm to assess out-

oxygenation variables may become important determinants of

comes and adverse events. Study arms that show significant im-

benefit/risk for the subjects as explained above; thus, these

provement may ethically preclude the deployment of other arms.

variables may be proposed as further determinants for cessa-

Similarly, study arms that show adverse events (as listed) attrib-

tion rules.

utable to the intervention (per trial team with DSMB/IRB deter-

• Enrollment/refusal rates: Modifications on enrollment and con-

mination) or minimal/no improvement may be eliminated. Study

sent procedure may be proposed to remedy low enrollment and

arms may be added if concurrent trials demonstrate significant

high refusal rate. One potential alternative is the addition of an

evidence of benefit of a different route, dose, or mode of admin-

observational arm as done by Pieracci et al.37

istration of the study drugs.

• Crossover: If 1 treatment arm shows a signal of benefit (as defined

• Inclusion criteria: Although currently the trial entry criteria

in our proposed outcomes), we are under the ethical mandate to

are based on age and PaO2 /FiO2 , we recognize the potential

offer it to patients who were enrolled in the other arms but did

role of coagulation assays (eg, D-dimer, fibrinogen, fibrinolysis)

not show improvement. These patients “cross over” to the alter-

in better defining the group most likely to benefit from the

native arm. The analysis will be conducted as an intent-to-treat

fibrinolytic intervention. Thus, such assays may be added as

approach (patients are analyzed according to their initial assigned

entry criteria if identified as predictors of good results during

group) and subsequently in a separate as-treated analysis consid-

interim analyses or in other clinical trials. In addition, if the

ering the combination of the 2 treatments.

stratified analysis on initial PaO2 /FiO2 shows benefit or harm

• Comparison of prone/supine position: Additional arms or

in low and moderate PaO2 /FiO2 , the PaO2 /FiO2 level for entry

change in entry criteria may have to added if the prone posi-

in the study may be modified to increase the probability of

tion for ventilation is demonstrated to have a major benefit (eg,

benefit.
• Sample size: The current sample size is defined by budget and

criteria for entry may be modified to PaO2/FiO2 <150 in prone
position).

feasibility constraints and may prove insufficient if the effect

• Doses/duration/administration mode of t-PA and heparin: As

detected is substantial but there is low power to detect it. A

more is learned during this trial as well as other clinical trials

larger sample size may be recommended by the trial team and the

about the administration of t-PA in relation to other venti-

DSMB, in which case we will pursue additional resources to in-

lation techniques (prone position, PEEP, pulmonary vasodi-

crease enrollment.

lators, etc) and the risk/benefit associated with the doses,

990

|

MOORE et al.

duration, and model of administration (eg, bolus vs continu-

2.13 | Follow-up

ous drip), it may be beneficial for study subjects to modify the
study arms.

Patients will be followed until death or discharge up to 28 days.
Laboratory measurements related to the research study, however,

2.11 | Laboratory measurements

will end at day 7 after randomization.

Laboratory tests obtained on all patients will include:

2.14 | Statistical analysis

1. Arterial blood gases, fibrinogen and D-dimer levels, prothrombin

The statistical analysis plan followed the recently published guide-

time/International Normalized Ratio, aPTT, C-reactive protein, and

lines40 and is available in the Supplemental Material. All outcome

complete blood count with platelet count: pre and post alteplase

variables will be examined for distribution. If very skewed, we will at-

intravenous bolus (only baseline for controls), then every 6 hours for

tempt log and Box-Cox power transformations to approximate nor-

the first 24 hours, and once a day for 7 days (or earlier if patient

mality. If those are unsuccessful, the outcomes will be categorized

is extubated) following treatment intervention in all the groups.

using the median or previously defined cutoff. All outcomes will also

2. Thrombelastography (TEG) or rotational thromboelastometry

be analyzed as relative change from baseline. Effectiveness of the

(ROTEM) (where available): pre and post alteplase intravenous

randomization to determine baseline comparability of the groups

bolus (baseline for controls), then every 6 hours for the first

will be done using the absolute standardized mean difference (SMD

24 hours, and once a day for 7 days (or earlier if patient is extu-

<0.20 defined as acceptable balance). Any differences deemed clini-

bated) following treatment intervention in all the groups.

cally relevant or with absolute SMD >0.2 will be adjusted for using

3. Troponin, creatinine, bilirubin, alanine aminotransferase, and creatine kinase pre-alteplase (baseline for controls) and at 24 and 72
hours after infusion.

inverse probability weighting methods as described below.
All outcome comparison analyses will be conducted initially as
an intent-to-treat (patients are analyzed in the group they were
randomized to), followed by an as-treated analysis. The primary

2.12 | Safety assessment

outcome will be assessed within groups and between groups.
Differences in the primary outcome will be evaluated using linear mixed models, with appropriate transformations if normality

Safety considerations and monitoring with plan during the interven-

departure of residuals is detected. Linear mixed models allow (i)

tion administration are listed in Table 3. The estimated risk of the

adjustment for potential confounders detected in the comparison

most feared complication, intracranial hemorrhage, is estimated

of the groups at baseline using inverse probability weighting by

to be 0.72%28 if total t-PA dose is <1.4 mg/kg over total infusion.

a propensity score; and (ii) change in the covariance structure to

Estimated risk of severe or life-threatening bleeding other than

account for repeated measures and the intrahospital correlation

intracranial is 0.4%38 if total t-PA dose is <1.4 mg/kg over total

(as this is a multicenter study). In addition, it tolerates missing ob-

infusion. Given the emergence of data on the increased rate of

servations. We will also compare percent change over baseline,

thrombotic strokes in young patients with COVID-19, 27 exclusion

using t tests with the appropriate adjustment for heteroscedas-

of stroke prior to fibrinolytic therapy is essential. The inability to

ticity if needed. Categorical outcomes will be compared using

demonstrate a normal neurological exam unless a CT scan within

generalized estimating equations to account for confounders (as

39

of enrollment excludes a cerebral vascular event repre-

above), covariance structure and intrahospital correlation. In addi-

sents an absolute exclusion to study enrollment. Safety assessments

tion, we will compare the “dose” of the intervention (ie, how much

will consist of monitoring and reporting adverse events and serious

of the treatment the patient received) as an effect of interest, as

adverse events per protocol. This includes any adverse event, de-

premature death and withdrawals are expected. Survival analysis

fined as any unfavorable and unintended sign (including an abnor-

with inverse probability weighted Cox proportional hazards model

mal laboratory finding), symptom, or disease temporally associated

and robust sandwich variance estimate to account for clustering

with the use of alteplase or other protocol-imposed intervention (eg,

for hospitals will be used for mortality as well as for survivor-bias

heparin, blood sampling). Given alteplase and heparin relative short

subject outcomes (eg, pulmonary embolism) censoring for death.

4.5 hours

half-life (<72 minutes and <90 minutes, respectively), any adverse

As all outcomes are in-hospital, loss to follow-up is not likely. The

event manifesting within 3 hours of administration of the interven-

preplanned comparisons include within group (improvement over

tion drugs would be considered potentially temporally related to the

baseline) and between groups, all 2-tailed with significance de-

intervention drugs. Adverse events associated with blood sampling

clared as defined by the Pocock spending method.

are considered temporally related if happening within 30 minutes of

There will be no adjustment for multiple outcomes, as all were

the sampling. Methods and timing of safety check assessments are

preplanned. Adjustments for multiple comparisons in preplanned

listed in Table 3.

hypotheses leads to more type II errors.41,42
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TA B L E 3

Safety check assessments: methods and timing

Serious adverse
events

Method for safety check

Safety check frequency

Cessation rulea

Death

NA

NA

NA

Cardiopulmonary
arrest

NA

NA

Any cardiopulmonary arrest

Allergic reactions
including
angioedema

Clinical exam

Clinical exam before, during, and immediately after alteplase
infusion; every 6 h after alteplase infusion up to 24 h; at
least every 24 h after alteplase infusion during heparin
infusion or more frequently if any abnormality detected

Any allergic reaction

Worsening of
neurological
function

Clinical neurological exam
and imaging if applicable
per care provider’s
decision. Most patients
will use GCS without
verbal component

Clinical exam before, during, and immediately after
alteplase infusion; every 6 h post alteplase infusion up to
24 h; at least every 24 h after alteplase infusion during
heparin infusion or more frequently if any abnormality
detected Imaging per attending’s discretion

GCS decrease of >2 points or
focal deficit within 24 h of
study drug infusion or new
hemorrhage on CT scan or MRI

Worsening of
pulmonary
function

Arterial blood gas and
ventilation indices

Every 6 h in the first 24 h and every 12 until 48 h; if
second alteplase dose, every 6 h until 48 h

>30% PaO2/FiO2 baseline
reduction

External bleeding

Clinical exam

Clinical exam before, during, and immediately after
alteplase infusion; every 6 h post alteplase infusion up to
24 h; at least every 24 h after alteplase infusion during
heparin infusion or more frequently if any abnormality
detected

Unresponsive to compression

Gastrointestinal
bleeding

Clinical exam and
hemoglobin

Clinical exam before, during, and immediately after
alteplase infusion; every 6 h post alteplase infusion up to
24 h; at least every 24 h after alteplase infusion during
heparin infusion or more frequently if any abnormality
detected. Endoscopic exam per attending's discretion.

Hemoglobin reduction >3 g/dL
within 24 hours of study drug
intervention or requiring RBC
transfusion with suspected
gastrointestinal bleeding

Hemoptysis

Clinical exam

Clinical exam before, during, and immediately after
alteplase infusion; every 6 h after alteplase infusion up
to 24 h; at least every 24 h after alteplase infusion during
heparin infusion or more frequently if any abnormality
detected. Endoscopic exam per attending’s discretion.

Persistent hemoptysis for ≥4 h
or compromising airway

Hematuria

Clinical exam

Clinical exam before, during, and immediately after
alteplase infusion; every 6 h post alteplase infusion up to
24 h; at least every 24 h after alteplase infusion during
heparin infusion or more frequently if any abnormality
detected. Endoscopic exam per attending’s discretion.

Persistent hematuria for ≥4 h or
urinary obstruction

Clinical exam pre, during and immediately post alteplase
infusion; every 6 h post alteplase infusion up to 24 h; at
least every 24 h after alteplase infusion during heparin
infusion or more frequently if any abnormality detected.
Endoscopic exam per attending's discretion.

Hemoglobin reduction >3 g/dL
within 24 h of infusion of study
drug infusion or requiring RBC
transfusion

Clinical exam before, during, and immediately after alteplase
infusion; every 6 h post alteplase infusion up to 24 h; at
least every 24 h after alteplase infusion during heparin
infusion or more frequently if any abnormality detected

Hemoglobin reduction >3 g/dL
within 24 h of infusion of study
drug infusion or requiring RBC
transfusion

Retroperitoneal
bleeding

a

991

Tube thoracotomy

Clinical exam and Hgb

Any of the below
listed criteria
developing during
or up to 3 h after
alteplase or
heparin infusionb

Clinical exam and
laboratory

Any of listed exclusion criteria
developing during or up to
3 h after alteplase or heparin
infusion, except for fibrinogen,
for which we will set cessation
cutoff at 100 mg/dL

Criteria or attending’s decision.

b

Criteria: Acute myocardial infarction; acute renal failure (escalating renal failure with creatinine >3 times baseline); liver failure (escalating liver
failure with ALT >3 times baseline); cardiac tamponade; bacterial endocarditis; severe uncontrolled hypertension defined as SBP >185 mm Hg or
DBP >110 mm Hg; seizure; placement on ECMO; major surgery required; requirement of lumbar puncture; INR >1.7; platelet count <100 × 109/L or
history of HITT; fibrinogen <100 mg/dL.
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2.15 | Preplanned subgroup analyses

believed to be the initiator of coagulation changes based on prior
work in sepsis.53 Cytokine production is believed to drive tissue

We anticipate the following subgroup analyses, which will assist

factor product, resulting in systemic activation of coagulation.54

in determining whether there is a subgroup of patients for whom

Tissue factor expression is upregulated on macrophages and endo-

the intervention is more beneficial/harmful: (i) baseline PaO2/

thelial cells in response to elevated tumor necrosis factor-α (TNF-α),

FiO2 < 100 and < 50; (ii) hemodynamic instability with vasopressors;

interleukin (IL)-6 and IL-1.55 At the same time, the cytokine storm

(iii) age <35, 36-50, 51-65, 66-75 years; (iv) D-dimers median levels;

damages the endothelium, reducing the antithrombic capacity of

(v) fibrinolysis shutdown (by TEG or ROTEM); (vi) fibrinogen median

the systemic circulation via suppression of protein C, protein S, anti-

levels; (vii) prone/supine positioning; (viii) requirement of rebolus-

thrombin, and tissue factor pathway inhibitor.56 This is compounded

ing of lteplase; (ix) received dose of alteplase as premature death or

by the severe acute respiratory syndrome coronavirus 2 directly

adverse event or other reasons may preclude the administration of

infecting the endothelium of the lungs, heart, and small bowel.57

complete treatment; and (x) elimination of centers contributing <2

COVID also is commonly associated with a high fibrinogen level that

cases.

correlates with IL-6 levels.45 IL-6 has previously been reported to be

Additional subgroup analyses may be defined at an interim analy-

the main stimulator of fibrinogen synthesis.58 With the combination

sis and will be added for the subsequent interim analyses. This will be

of coagulation activation and hyperfibrinogenemia it is not surpris-

documented by filing another version of this statistical analysis plan

ing that this population is prone to thrombosis.

with the IRBs, DSMB, funder, and FDA.

Endotoxin leading to cytokine production has also been demonstrated to activate of the fibrinolytic system 2 hours after infusion,
followed by a shutdown of fibrinolysis within the following hour

2.16 | Missing data

due to elevated plasminogen activator inhibitor −1 (PAI-1) levels. 59
Fibrinolysis activation with rapid suppression from PAI-1 was appre-

Missing data are expected to be minimal. If <15% and nondifferential

ciated with endotoxin infusion in nonhuman primates, with concur-

between study groups, we will proceed with analyses of complete

rent increases in thrombin generation.60 Pentoxifylline attenuates

data. If >15% or differential between groups (possibly missing not at

these fibrinolytic changes in this animal model, whereas IL-6 and

random), we will add 2 strategies to the complete data set analyses:

TNF-α inhibitors have no effect.61 These experiments were fol-

(i) multiple imputation by chained equations (MICE), recognizing that

lowed up with the hypothesis that an antifibrinolytic (eg, tranexamic

MICE is better for missing at random data; and (ii) sensitivity analy-

acid) would prevent progression to disseminated intravascular co-

ses: we will assume worst and best clinical scenarios and compare

agulation by blocking plasmin activation; however, tranexamic acid

the results with the complete data set.

had no impact on the prothrombic component of endotoxin infusion in healthy subjects and did not alter cytokine production.62

3 | DISCUSSION

Our group’s recent work has demonstrated that COVID-19 patients

The mechanistic rationale for the administration of t-PA (alteplase) is

with a thrombelastography Lysis 30 (LY30) of 0% and D-dimer

based on (i) autopsy findings of patients who succumbed to COVID-

level >2600 ng/mL have a venous thrombosis rate of 50%.63 Due

19 ARDS showing presence of microthrombi in the lungs and other
1,3

to D-dimers having a half-life that exceeds 12 hours,64 this value is

organs ; (ii) COVID-19 poor outcomes associated with hypercoagu-

reflective of the cumulative amount of polymerized fibrin present

lability/hypofibrinolysis 43-45; (iii) the high rate of pulmonary throm-

over the past day or longer, while low fibrinolytic activity measures

botic complications while on prophylactic heparin dosing46; (iv) and

the current fibrinolytic systemic state of the patient. Therefore, an

previous demonstrations of improved pulmonary function in ARDS

elevated D-dimer with low fibrinolytic activity is consistent with

with plasminogen activators with no bleeding complications. 25 The

prior activation of fibrinolysis with current low fibrinolytic activity,

pathophysiology of COVID can be conceptualized into an early

fulfilling the definition of fibrinolysis shutdown, which has been de-

phase, dominated by symptoms directly attributable to the virus,

scribed for the past half-century.65,66 This fibrinolytic phenotype

and a later phase manifesting the consequences of the inflammatory

has been associated with poor outcomes in trauma.67-71 Elevated

response to the invading pathogen. Much of the therapy currently

D-dimer and low fibrinolytic state has previously been mistermed

being investigated focuses of reducing the viral load and attenuating

overt hyperfibrinolysis72; however, the overt hyperfibrinolytic phe-

cell entry lacking and reducing inflammation.47-51 While the conspic-

notype in trauma does not commonly bleed to death and receives

uous hypercoagulable state has been widely documented, the role of

significantly fewer transfusions compared to patients with elevated

suppressed fibrinolysis remains largely overlooked.

D-dimer and elevated LY30s that represents true hyperfibrinolysis.

COVID-19 has a clear association with thrombotic complications,

Hyperfibrinolytic trauma patients have the hallmark signs of exces-

which predominantly occur in the lungs.46 Coagulation biomarkers

sive fibrinolysis with excessive bleeding and low fibrinogen levels

Functional coagulation

that can be reversed with an antifibrinolytic medication.73 Patients

measurements have further supported the hypercoagulable state of

with COVID-19 have elevated fibrinogen but are not bleeding to

these patients.43 While the mechanism of thrombosis and hyperco-

death and should not be classified as hyperfibrinolytic, which has al-

agulability remains unclear, inflammation driving cytokine release is

ready been proposed.74 The combination of prothrombotic and lack

have been associated with poor prognosis.

52
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of fibrinolysis poses a major logistical challenge in treating COVID-

efficiency of the trial and increasing the likelihood of isolating the

19, as both ends of coagulation likely require treatment for effective

more successful arm.

outcomes. There is a potential that a combination of IL-6 blockage

It should be noted that using the traditional (yet arbitrary) confi-

to attenuate hyperfibrinogenemia in combination with t-PA could

dence level of 95% (α = 0.05) is overly stringent for the current cir-

provide a more durable response, which can be adapted from this

cumstances. The rigid cutoff of 95% level of certainty, as eloquently

phase II trial.

summarized by Nuzzo85 in one of the most cited Nature articles

The 48-hour assessment of PaO2/FiO2 in patients after t-PA

should not be applied without regard to the conditions in which the

treatment will also have limitations in quantifying pulmonary dys-

study is conducted. Is it appropriate or necessary to be 95% cer-

function improvement. There a numerous ventilator adjuncts to

tain when the condition in question has high lethality and morbidity,

improve oxygenation in the setting of severe ARDS, including pron-

threatening to exceed the health care system’s capacity, and has no

ing the patient,11 paralytics,75 nitric oxide,76 and prostonoids.77

known prevention (except for isolation) or treatment? While we do

Prolonged use of these interventions is associated with adverse

not believe this is the precise time to reignite a discussion about the

events.78 Therefore, getting the patients off of these medications

traditional probability (P < .05), we will, in our study, for all compar-

or prone positioning would be considered a beneficial outcome with

isons present the effect size with appropriate confidence intervals

t-PA regardless of change in PaO2/FiO2 over 48 hours. This also in-

depicting the uncertainty surrounding our estimation. The clinical

cludes reducing toxic levels of oxygen (FiO2 > 80%) and reducing

experience of the investigators working together with the indepen-

PEEP. In addition to assessing improvements in each of these indi-

dent DSMB and IRBs will produce the appropriate interpretation of

vidual variables, a composite score of each adjunctive measure will

the results, which can then inform current medical decisions and a

also be conducted to represent a global change in requirement of

subsequent phase III trial if appropriate. Peer review and the read-

adjuncts for improving oxygenation at 48 hours.

ers can then assess the results applying their own tolerance for

Due to different treatment practices at the 5 enrolling centers,

uncertainty.

we anticipate that there will be variability in the techniques used

Two phase I clinical trials support the potential beneficial effect

before patient enrollment to optimize oxygenation, an acknowl-

of thrombolytics in severe ARDS with no reported bleeding compli-

edged limitation. This is in line with the pragmatic nature of the

cations24,25 and prompted our group’s interest in the potential use

trial. Moreover, the crisis created by the pandemic without available

of t-PA in COVID-19. 86 An important observation was that patients

treatments precluded the development of agreed-upon standard

can have transient responders to lytic therapy, with autopsy confir-

operating procedures for ventilation as well as other intensive care

mation of subsequent pulmonary rethrombosis. 24 Our early off-la-

procedures.

bel use of t-PA in COVID-19–related ARDS demonstrated similar

During the current pandemic, there has been a call for rigor79

transient or long-lasting improvement on patients using lower doses

However, random-

of this medication. 87 Redosing of fibrinolytics in the Hardaway

ized controlled trials bring ethical dilemmas, especially when no

et al25 study when indicated demonstrated an overall improvement

current treatment exists. Thus, it is imperative that creativity and

in oxygenation in 80%. These observations stress the importance

the rigorous application of the scientific method are combined to

of continued heparin anticoagulation following fibrinolytic therapy,

produce an innovative, efficient study design. Our design uses the

as proposed in our trial, together with redosing t-PA as needed. In

adaptive framework,80,81 which allows preplanned modifications to

both prior phase I clinical trials using fibrinolytics in the setting of

improve the efficiency of the trial and detect effect or harm more

ARDS, 24,25 the conclusions made clear that future follow-up studies

promptly, and a modified stepped-wedge design. More recently, the

were required. Our proposal for a phase II study is the natural pro-

stepped-wedge randomized trials have gained popularity have been

gression to expand upon those preliminary findings to identify the

proposed.82,83 The modified stepped-wedge pragmatic design is dif-

optimal dosing of a fibrinolytic in the setting of ARDS and ensure

ferent than the usual parallel randomized controlled trials, in which

safety in regards to treatment strategies using t-PA, which is a com-

the intervention and control groups run, as the name implies, in par-

monly used fibrinolytic agent in clinical practice.

ous trials with concurrent control groups.

allel. The traditional stepped-wedged approach involves a sequential rollout of an intervention to participants (individuals or clusters)
over a number of time periods, such that at the end of the study, all
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